Baricitinib Maintains Regrowth of Hair, Eyebrows, and Eyelashes Over 3 Years

The long-term extension of the BRAVE-AA studies showed that over 80% of patients with alopecia areata (AA) who responded to baricitinib therapy at week 52 maintained their response until week 152. The studies involved 1,200 adults with ≥50% hair loss, who were given either 2 mg or 4 mg of baricitinib daily. After 3 years, 89.1% of participants treated with the high dose and 83.6% treated with the low dose maintained a Severity of Alopecia Tool (SALT) score ≤20. Additionally, the proportion of participants achieving full or nearly full eyebrows and eyelashes increased from week 52 through week 152. For the 4 mg group, 80% had full or nearly full eyebrows and 80.9% had full or nearly full eyelashes at week 152. For the 2 mg group, these percentages were 66.7% and 78.1% respectively.